Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →
Braveheart Bio closes upsized Initial Public Offering raising $439.9 million with full exercise of underwriters' option for additional shares. The shares began trading on Nasdaq under the ticker 'BRVE'.
Braveheart Bio, Inc. announced the closing of its upsized initial public offering of 24,437,500 shares at $18.00 per share, totaling gross proceeds of $439.9 million. The offering included the full exercise of the underwriters' option to purchase additional shares. Joint book-running managers for the offering included Goldman Sachs & Co
Company Information
Company
Braveheart Bio
Location
San Francisco, California, United States
About
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
Related People
Suggested for you
2 contacts
Verified contactsNo contacts on file at Braveheart Bio yet.
Predictive Intelligence
Strategic
ML-powered predictions for Braveheart Bio's next move
San FranciscoBiotechnologyHealth Care